Psilocybin has attracted considerable attention as a potential treatment for depression, particularly among people who have not experienced adequate relief from conventional antidepressant medications. While much of the public discussion focuses on psychedelic mushrooms or psilocybin therapy generally, one specific investigational treatment has emerged as a leading candidate for FDA approval. Known as COMP360, the treatment is being developed by Compass Pathways for adults with treatment-resistant depression.
COMP360 represents an important development because it is designed to bring psilocybin into a standardized medical treatment setting. Rather than relying on naturally occurring mushrooms or unregulated psychedelic experiences, the treatment uses a precisely manufactured formulation administered under professional supervision. Following positive late-stage clinical trial results, Compass Pathways completed its New Drug Application submission to the U.S. Food and Drug Administration on November 9, 2026.
Although COMP360 is not yet FDA-approved, its progress through clinical development may help determine how prescription psilocybin treatment becomes available in California and throughout the United States.
What Is COMP360 Psilocybin?
COMP360 is a proprietary synthetic formulation of psilocybin developed by Compass Pathways, a biotechnology company focused on treatments for mental health conditions. Psilocybin is the psychoactive compound found in certain species of mushrooms, but COMP360 is manufactured under controlled pharmaceutical conditions to provide consistent dosing and quality.
Once administered, psilocybin is converted by the body into psilocin, which interacts with serotonin receptors in the brain. Researchers believe these effects may temporarily alter patterns of brain activity associated with mood, perception, and emotional processing. Scientists are also investigating whether these changes may create opportunities for lasting improvements in depressive symptoms, although the precise mechanisms underlying clinical benefit remain under investigation.
The distinction between COMP360 and traditional psilocybin mushrooms is important. COMP360 is a specific investigational drug product evaluated through controlled clinical trials. Its safety and effectiveness findings cannot automatically be applied to every form of psilocybin, every dosage, or psychedelic experiences conducted outside medical supervision.
What Is COMP360 Being Developed to Treat?
The primary indication being pursued by Compass Pathways is treatment-resistant depression, commonly defined as depression that has not responded adequately to at least two appropriate courses of antidepressant treatment. People with treatment-resistant depression may continue experiencing persistent sadness, loss of interest, difficulty concentrating, disrupted sleep, fatigue, and significant impairment in daily functioning despite receiving established treatments.
For some patients, repeated medication trials provide limited improvement or cause side effects that make continued treatment difficult. Psychotherapy, medication adjustments, transcranial magnetic stimulation, and other interventions may be considered, but no single approach works for everyone. This ongoing clinical need has encouraged researchers to investigate treatments that work through different biological mechanisms.
COMP360 is being studied as a potentially intermittent treatment rather than a medication taken every day. The clinical research has examined whether supervised psilocybin administration can produce meaningful improvements in depressive symptoms over subsequent weeks and months. Compass Pathways is also conducting research involving post-traumatic stress disorder, although its initial FDA application focuses on treatment-resistant depression.
What Have Clinical Trials Found?
Compass Pathways has conducted a substantial clinical development program that includes a Phase 2b study and two Phase 3 trials, known as COMP005 and COMP006. These studies evaluated the effects of COMP360 on depressive symptoms using established clinical rating scales, including the Montgomery-Åsberg Depression Rating Scale.
In 2026, Compass reported that both Phase 3 trials met their primary endpoints, demonstrating statistically significant improvements in depression severity under the conditions studied. The company also released follow-up findings suggesting that some participants experienced sustained benefits and that additional treatment could provide further improvement for certain patients.
In September 2026, Compass reported 52-week open-label follow-up findings from COMP005. Among participants receiving an additional 25 mg dose during the later phase of the study, researchers observed further reductions in depressive symptoms. These results provide information about the possibility of longer-term benefit, but open-label findings require careful interpretation because participants and investigators know which treatment is being administered.
The findings are encouraging, particularly for a population with limited treatment options. However, clinical trial success does not mean every patient will respond, that benefits will necessarily last for a year, or that the treatment is appropriate for everyone. The FDA must independently evaluate the complete evidence, including effectiveness, adverse events, manufacturing quality, and the proposed conditions of administration.
How Would COMP360 Treatment Work?
COMP360 is not being developed as a conventional prescription that patients would collect from a pharmacy and take independently at home. The clinical trial model involves preparation, a supervised dosing session, and psychological support afterward.
Before treatment, participants undergo clinical screening to evaluate their psychiatric history, medical conditions, current medications, and potential safety concerns. Preparation also helps individuals understand what to expect during a psychedelic experience, including temporary changes in perception, emotions, and awareness.
During the dosing session, the participant receives COMP360 in a controlled clinical environment with trained personnel present. The effects of psilocybin can last several hours, so treatment requires an extended appointment and continued observation. Participants may experience changes in sensory perception, emotional intensity, or their sense of time and self. Some experiences may be personally meaningful, while others can be uncomfortable or anxiety-provoking.
Afterward, participants receive psychological support and follow-up assessments. These appointments may help them discuss their experiences, monitor symptoms, and determine whether additional clinical care is needed. The research model includes supportive interactions, but COMP360 is not necessarily being developed with the same intensive psychotherapy requirements used in MDMA-assisted therapy trials.
The precise staffing, monitoring, and follow-up requirements for any commercially available treatment will depend on the FDA’s final decisions.
Does COMP360 Require Psychotherapy?
One of the important questions surrounding COMP360 is whether patients would be required to participate in formal psychotherapy as part of treatment. In clinical trials, COMP360 has been administered with a structured psychological support model that includes preparation, supervision, and follow-up. However, psychological support is not necessarily equivalent to a separate course of psychotherapy.
This distinction could influence how the treatment is delivered if approved. A psychiatric treatment center may be able to provide appropriate monitoring and supportive care without operating an extensive psychotherapy program. Conversely, some patients may benefit from ongoing counseling before or after treatment, particularly when depression occurs alongside trauma, anxiety, relationship difficulties, or other mental health concerns.
It is also important to distinguish COMP360 treatment from psychedelic integration therapy. Integration generally refers to counseling or supportive services that help individuals process and apply insights from psychedelic experiences. Integration services may be available independently of drug administration, but they do not provide access to COMP360 itself.
Until the FDA establishes final prescribing and administration requirements, patients should not assume that a particular counseling arrangement will be mandatory or that the medication will be available without professional supervision.
Is COMP360 Safe?
Clinical trials have identified adverse effects associated with COMP360, including headache, nausea, anxiety, and temporary changes in blood pressure. The intensity of a psychedelic experience may also create psychological distress, particularly for individuals who are unprepared or have certain psychiatric vulnerabilities.
Careful screening is therefore an important part of the investigational treatment model. A clinician must consider psychiatric history, current symptoms, cardiovascular health, medication use, and other factors before determining whether participation is appropriate. People with certain histories of psychosis or bipolar disorder may face additional concerns, and the final approved population may be narrower than the general population seeking psychedelic therapy.
Suicidality also requires careful assessment in people with treatment-resistant depression. The FDA’s evaluation includes whether the treatment’s potential benefits outweigh its risks and whether additional safeguards are needed.
COMP360 should not be viewed as a risk-free alternative to antidepressants or psychotherapy. Its potential value depends on appropriate patient selection, clinical supervision, and evidence-based follow-up care.
What Is the FDA Approval Status of COMP360?
On November 9, 2026, Compass Pathways announced that it had completed submission of its New Drug Application for COMP360 to the FDA. The application is supported by its late-stage clinical research program, including two positive Phase 3 trials.
COMP360 has received FDA Breakthrough Therapy designation, which is intended to facilitate the development and review of treatments for serious conditions when preliminary clinical evidence suggests substantial improvement over available therapies. Compass has also reported access to an expedited review pathway through a Commissioner’s National Priority Voucher.
These developments may shorten the time required for regulatory review, but they do not guarantee approval. The FDA must still determine whether the submitted evidence supports the proposed indication and whether the treatment can be used safely under the recommended conditions.
Compass Pathways has indicated that it is preparing for a potential commercial launch during the first half of 2027, subject to FDA approval and the necessary controlled-substance scheduling changes. That is the company’s anticipated timeline rather than a confirmed date when patients will be able to receive treatment.
Will COMP360 Be Available in California?
If COMP360 receives FDA approval, California could become an important market for its clinical introduction. The state has an extensive network of psychiatrists, behavioral health organizations, academic medical centers, and facilities already providing supervised treatments such as ketamine or esketamine.
Nevertheless, FDA approval would not automatically make COMP360 available at every psychiatric practice or psychedelic therapy center. Providers may need specialized training, appropriate clinical facilities, extended appointment capacity, and procedures for monitoring patients during and after administration. Controlled-substance requirements and any FDA-mandated safety program could also affect how quickly treatment becomes available.
Insurance coverage will be another important consideration. Even if the medication is approved, insurers will need to determine coverage criteria, reimbursement arrangements, and any requirements involving prior treatment history. Patients may encounter differences in availability and out-of-pocket costs depending on their insurance plans and geographic location.
For individuals in Los Angeles, the Bay Area, San Diego, Orange County, Sacramento, and other California regions, the practical question will eventually become which qualified providers are offering the approved treatment and whether they are accepting new patients.
How Is COMP360 Different From Other Psilocybin Therapy?
The term psilocybin therapy can refer to several different activities, including participation in clinical research, supervised treatment programs in jurisdictions with specific legal frameworks, and counseling related to psychedelic experiences. These activities are not interchangeable.
COMP360 is a pharmaceutical formulation being evaluated for a specific psychiatric indication. If approved, it would be prescribed and administered according to its FDA-approved labeling and applicable federal and state requirements. Approval would not automatically authorize all forms of psilocybin-assisted therapy or the use of naturally occurring psychedelic mushrooms in ordinary clinical practice.
Other researchers and organizations are developing different psilocybin formulations and treatment approaches. Their clinical evidence, dosing protocols, and regulatory pathways may differ from those of Compass Pathways.
Patients considering future treatment should understand which specific medication or program a provider offers, what evidence supports its use, and whether it is legally available for the condition being treated.
What Should Patients Do While COMP360 Is Awaiting Approval?
Individuals experiencing treatment-resistant depression should continue working with qualified healthcare professionals rather than delaying established care in anticipation of a future psychedelic treatment. A comprehensive psychiatric evaluation can help determine whether previous treatments have been adequate and whether additional evidence-based options may be appropriate.
Patients interested in COMP360 can monitor FDA announcements, follow developments from Compass Pathways, and review clinical trial opportunities through recognized research registries. They should also be cautious about businesses claiming to provide FDA-approved COMP360 before approval has occurred.
For people interested in psychedelic-assisted treatment more broadly, learning about screening, preparation, supervised administration, and psychological support can help establish realistic expectations. The arrival of a regulated psilocybin medication would represent an important change in treatment access, but it would remain a medical intervention requiring careful evaluation.
The Future of COMP360 and Psilocybin Treatment
COMP360 has progressed further through clinical development than many psychedelic treatment candidates, and the completion of its FDA application represents a major milestone for the field. Its research program is helping answer questions about whether a standardized psilocybin formulation can provide meaningful relief for people with difficult-to-treat depression and how such treatment might fit into established psychiatric care.
The next stage will determine whether the evidence is sufficient for approval and what restrictions, clinical requirements, and reimbursement arrangements may accompany commercial availability. Those decisions will shape the experience of patients and providers far more directly than the broad enthusiasm surrounding psychedelic medicine.
For Californians following these developments, COMP360 is worth understanding as a specific investigational treatment with a defined clinical and regulatory pathway. It is not yet an available prescription option, but its progress may help establish how medically supervised psilocybin treatment is delivered in the years ahead.
Learn More About Psychedelic Therapy in California
Whether you’re exploring treatment options or looking for information specific to your region, continue your research with these guides.
Treatment Guides
- MDMA Therapy in California
- Psilocybin Therapy in California
- Ketamine Therapy
- Psychedelic Integration Therapy
- Psychedelic Clinical Trials California